TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02064400

Intervention type: OTHER
Intervention: Musculoskeletal Ultrasound
Description: 7-joint musculoskeletal ultrasound scan

Intervention type: OTHER
Intervention: Semi-structured patient interview
Description: Semi-structured patient interview
Study: NCT00219349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 14 weekly sessions of individualized CBT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: 10-20 mg per day for 12 weeks
Study: NCT00604760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEM 3454
Description: Capsule 5 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEM 3454
Description: Capsule 15 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEM 3454
Description: Capsule 50 mg once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MEM 3454
Description: Capsule once a day
Study: NCT04130477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tunnel attachments and light Nickel Titanium wire
Description: Tunnel attachments planned virtually and light Nickel Titanium wire

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Aligner therapy
Description: Clear Aligner therapy
Study: NCT04525066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Hyaluronic Acid Injection Injection
Description: Patients in the placebo group did not receive hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
Study: NCT01389856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
Study: NCT00731640

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReSTOR
Description: AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
Study: NCT02221674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol
Study: NCT04104607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-1, PSMAxCD3
Description: Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation
Study: NCT02484209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1500 mg daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: glimepiride 2-4 mg twice daily for 16 weeks
Study: NCT03754517

Intervention type: DIAGNOSTIC_TEST
Intervention: RPR Titer
Description: RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: RPR Titer
Description: RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
Study: NCT02484209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 1500 mg daily for 16 weeks
Study: NCT01065077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Infusion of 150 µg/h during 48h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Infusion of 100 µg/h during 48h
Study: NCT03754517

Intervention type: DIAGNOSTIC_TEST
Intervention: RPR Titer
Description: RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
Study: NCT00337207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.
Study: NCT03565783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV
Study: NCT04657536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high frequency fulguration equipment
Description: All subjects will be carried out with 3 standard protocol TRF treatments to the vulvovaginal tissue using the high frequency fulguration equipment (Shenzhen Peninsula Medical co., Ltd) at 10-day to 15-day intervals. Radiofrequency energy was applied to the vaginal canal through a specialized probe combining monopolar and bipolar treatment modes. Monopolar treatment mode is for 15 minutes. Aim the three indication points A, B and C on the probe to the direction of 12 o'clock in turn. Each area should be treated for about 5 minutes. Rotate the probe clockwise when changing the area for treatment.Bipolar treatment mode is for 10 minutes. Firstly, indication point A is aimed to 12 o'clock for 5-minutes treatment and then the probe is rotated 90°clockwise for another 5-minutes treatment. The power setting will be 35-40w, and the target temperature setting will be 40 to 45℃, titrated to subject tolerance.
Study: NCT01464177

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic hypofractionated RT 5x5Gy
Description: Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic hypofractionated RT 5x7Gy
Description: Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization.
Study: NCT01065077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Infusion of 50 µg/h during 48h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of placebo during 48h
Study: NCT02772159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208
Description: One dose each of treatments A: \[14C\] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: \[14C\] TD-4208 200 μg oral solution administered in a fasted state.
Study: NCT03330275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Contact Lens
Description: JJVC senofilcon A-based contact lens with new UV-blocker
Study: NCT03385226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 12Gy in 3 fractions
Study: NCT01196026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: One or two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: One or two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: One or two intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™ Junior
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™ Junior
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™ Junior
Description: Two intramuscular injections
Study: NCT00837213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide with clindamycin
Description: Benzoyl peroxide wash - Clindamycin foam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide with clindamycin and doxycycline
Description: Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
Study: NCT02855268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lademirsen (SAR339375)
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
Study: NCT02396706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivy Leaves Cough Liquid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03202563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin 50mg
Description: For patients who have been randomized to Gemigliptin(Experimental arm), the patients continue to take a gemigliptin 50mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: For patients who have been randomized to Dapagliflozin(Active Comparator arm), the patients continue to take a dapagliflozin 10mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))
Study: NCT04239976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Assessment Test
Description: Undergo gait assessment test
Study: NCT03202563

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diet/exercise questionnaire
Description: doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diet/exercise questionnaire
Description: doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring System(CGMS)
Description: For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System(CGMS)
Description: For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
Study: NCT01540357

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based therapy
Description: Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment after waiting time
Description: Treatment was performed after completion of the active arm.
Study: NCT01543074

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BSE placebo
Description: 2 pills = 0 micromoles of Sulforaphane/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BSE placebo
Description: 2 pills = 0 micromoles of Sulforaphane/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garlic oil
Description: 1 pill = 30 mg garlic oil/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garlic oil
Description: 1 pill = 30 mg garlic oil/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BSE
Description: 2 pills = 200 micromoles of Sulforaphane/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BSE
Description: 2 pills = 200 micromoles of Sulforaphane/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Garlic Oil Placebo
Description: 1 pill = 0 mg garlic oil/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garlic Oil Placebo
Description: 1 pill = 0 mg garlic oil/day
Study: NCT02351765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acelarin
Description: First-in-class nucleotide analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Platinum-compound chemotherapy drug
Study: NCT02072265

Intervention type: DEVICE
Intervention: Infrared thermal images

Intervention type: DEVICE
Intervention: Infrared thermal images
Study: NCT01034930

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of dental implants
Description: Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of dental implants
Description: Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of dental implants
Description: Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.
Study: NCT01568840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation Group
Description: Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in manual therapy maneuvers and global postural reeducation treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Segmental Exercises Group
Description: Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in segmental exercises (stretching and strengthening) treatment.
Study: NCT02345473

Intervention type: GENETIC
Intervention: Detection of circulating tumor cells in blood samples
Description: Ficoll based isolation of mononuclear cells from the peripheral blood of patients undergoing radical cystectomy, nucleic acids extraction and, finally, PCR based detection of sequences specific to cytokeratins.

Intervention type: GENETIC
Intervention: Detection of circulating tumor cells in blood samples
Description: Ficoll based isolation of mononuclear cells from the peripheral blood of patients undergoing radical cystectomy, nucleic acids extraction and, finally, PCR based detection of sequences specific to cytokeratins.
Study: NCT05565703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PARO Robotic Seal Intervention
Description: PARO is a therapeutic robot used to comfort PWD exhibiting agitation and restlessness (www.parorobots.com). Participants are brought out to the activity are on the ACE Unit and provided with an isolation gown to wear during their interaction with the seal. The robot is then placed on their laps for them to hold on their laps, pet, rock and pick up. The participants can also brush the robot and/or give it a bath with baby wipes. The researcher encourages participant engagement with the robot. If the participant does not want the robot on their lap it is placed on a bedside table for them to interact with.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The participants are randomly assigned and receive a one hour visit by the researcher or research assistant
Study: NCT04131946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-Based (Intervention Arm)
Description: Community dispensed FIT
Study: NCT01295593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid and 2-chlorodeoxyadenosine
Description: VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles
Study: NCT04041154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Fatigue
Description: Participants will perform a cognitively demanding task (spatial attention task), repeatedly, to induce cognitive fatigue.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Fatigue
Description: Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rewarding Stimuli
Description: Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
Study: NCT00986843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM30181AK tablet + Irinotecan tablets
Description: HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
Study: NCT04132310

Intervention type: OTHER
Intervention: N/A This is an observational study.
Description: This is an observational study.
Study: NCT01749878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1500
Study: NCT04657536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: promestriene vaginal soft capsules
Description: Promestriene vaginal soft capsules（Zhejiang Anbao Pharmaceutical Co. LTD）will be used 10mg once a day for continuous 20 days.
Study: NCT02256891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRFM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double Row

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double Row
Study: NCT02150174

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Retrieval practice effect using word pairs and cued recall tests with feedback
Description: In the first phase (encoding), people study a list of 48 word pairs non semantically associated.~Then (initial test), they recall half of word pairs or restudy the other half.~In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval practice effect using word pairs and cued recall tests with feedback
Description: In the first phase (encoding), people study a list of 48 word pairs non semantically associated.~Then (initial test), they recall half of word pairs or restudy the other half.~In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs.
Study: NCT01563575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fast-track implementation process
Description: Undergo fast-track implementation process (WHO-HPH recognition Process), including: baseline data collection, quality plan, implementation for one year, follow-up data collection, revision of quality plan, external site visit and data validation
Study: NCT02457533

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle behavioral. Health plan, telephone support
Description: 'Lifestyle behavioral. Health plan, telephone support'
Study: NCT00839293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: Once, see arm description for more information

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: Once, see arm description for more information
Study: NCT04586803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
Study: NCT03330275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Contact Lens
Description: JJVC senofilcon A-based contact lens with new UV-blocker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Contact Lens
Description: JJVC senofilcon A-based contact lens with new UV-blocker
Study: NCT04586803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.